ArticleMedical decision making : an international journal of the Society for Medical Decision Making2018
Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia.
Article in Medical decision making : an international journal of the Society for Medical Decision Making, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC).British journal of cancer · 2022Pooled it
- A Tutorial on Discrete Event Simulation Models Using a Cost-Effectiveness Analysis Example in R.Medical decision making : an international journal of the Society for Medical Decision Making · 2026Article
- Outcomes of Density-Targeted Supplemental Breast Magnetic Resonance Imaging Screening by Breast Cancer Risk: Long-Term Health and Economic Considerations.Annals of internal medicine · 2026Article
- Five-Year Absolute Risk-Based and Age-Based Breast Cancer Screening in the US.JAMA network open · 2026Article
- Mathematical Modeling to Address Questions in Breast Cancer Screening: An Overview of the Breast Cancer Models of the Cancer Intervention and Surveillance Modeling Network.Journal of breast imaging · 2025Review
- Impact of different age ranges on the benefits and harms of the breast cancer screening programme by the EU-TOPIA tool.European journal of public health · 2024Article
- Article
- Assessing overdiagnosis of fecal immunological test screening for colorectal cancer with a digital twin approach.NPJ digital medicine · 2023Article
- The Early Detection of Breast Cancer Using Liquid Biopsies: Model Estimates of the Benefits, Harms, and Costs.Cancers · 2022Article
- Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort.Annals of internal medicine · 2022Article
- Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.JAMA oncology · 2022Article
- Bibliometric analysis of cancer care operations management: current status, developments, and future directions.Health care management science · 2022Review
- Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Article
- Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women.Journal of the National Cancer Institute · 2021Article
- Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.JAMA oncology · 2021Article
- Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts.PLoS computational biology · 2021Review
- Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore.BMC health services research · 2021Article
- Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.Journal of the National Cancer Institute · 2021Article
- Cost-effectiveness Analysis of Breast Cancer Screening Using Mammography in Singapore: A Modeling Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Modeling the natural history of ductal carcinoma in situ based on population data.Breast cancer research : BCR · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The MISCAN-Fadia microsimulation model uses continuous tumor growth to simulate the natural history of breast cancer and has been used extensively to estimate the impact of screening and adjuvant treatment on breast cancer incidence and mortality trends. The model simulates individual life histories from birth to death, with and without breast cancer, in the presence and in the absence of screening and treatment. Life histories are simulated according to discrete events such as birth, tumor inception, the tumor's clinical diagnosis diameter in the absence of screening, and death from breast cancer or death from other causes. MISCAN-Fadia consists of 4 main components: demography, natural history of breast cancer, screening, and treatment. Screening impact on the natural history of breast cancer is assessed by simulating continuous tumor growth and the "fatal diameter" concept. This concept implies that tumors diagnosed at a size that is between the screen detection threshold and the fatal diameter are cured, while tumors diagnosed at a diameter larger than the fatal tumor diameter metastasize and lead to breast cancer death. MISCAN-Fadia has been extended by including a different natural history for molecular subtypes based on a tumor's estrogen receptor (ER) status and human epidermal growth factor receptor 2 (HER2) status. In addition, personalized screening strategies that target women based on their risk such as breast density have been incorporated into the model. This personalized approach to screening will continue to develop in light of potential polygenic risk stratification possibilities and new screening modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.